Video

Aurion BioTech presents cell therapy findings with published clinical data

Author(s):

Kassi Jackson
Conferences|ASCRS

Greg Kunst, president and CEO of Aurion BioTech, shares a company update on endothelial cell therapy trials, clinical plans and upcoming data.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Key takeaways for enhanced patient care from Day 1
Related Content
Key lectures and awards at the AAO 2024 meeting
October 11th 2024

Key lectures and awards at the AAO 2024 meeting

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

MJH Life Sciences acquires EnVision Summit - ©dennisvdwater
October 9th 2024

MJH Life Sciences, parent of Ophthalmology Times, acquires EnVision Summit

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Verana Health debuts Qdata Explorer in advance of American Academy of Ophthalmology 2024 Annual Meeting
Published: October 9th 2024 | Updated: October 9th 2024

Verana Health debuts Qdata Explorer in advance of American Academy of Ophthalmology 2024 Annual Meeting

Site Logo
September 26th 2024

Las complejidades en la adopción de una nueva tecnología

© 2024 MJH Life Sciences

All rights reserved.